Breaking News, Financial News

Financial Report: WuXi PharmaTech 1Q

Biologics Services revenues up 75% in the quarter

By: Kristin Brooks

Managing Editor, Contract Pharma

WuXi PharmaTech

1Q Revenues: $180.0 million (+23%)

1Q Earnings: $17.8 million (flat)

Comments: Laboratory Services grew 21% to $114.3 million in the quarter. Small-Molecule Manufacturing Services increased 15% to $45.5 million. Biologics Services revenues were up 75% to $14.4 million.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters